In February 2023, RainMed’s caFFR was commercially launched in the Republic of Serbia and successfully completed its first charging case in Serbia’s national institute of cardiovascular diseases, KBC Dr Dragisa Misovic-Dedinje. During the use, caFFR’s high consistency (95.7%) and convenience has impressed all the experts and doctors. With the gradually expanded overseas market, RainMed is expected to realize its commercial layout and coverage of overseas market in advance. caFFR will be having a broader application prospect overseas.

RainMed's self-developed product caFFR is a coronary angiography-derived fractional flow reserve measurement system, which is based on two angiograms, real-time aortic pressure and a specially-designed computational fluid dynamics (CFD) model to measure FFR.  Compared with guidewire-based FFR, caFFR is relatively simple to operate, with low risk and short time. It avoids the use of invasive pressure guide wire and hyperemic agents, and therefore reduces the risk and cost for FFR measurement. With an extremely high diagnostic consistency of 95.7%, it provides clinicians an opportunity to expand the clinical application of coronary function evaluation.

In recent years, RainMed has actively strengthened its overseas sales foundation, increased overseas marketing channels, expanded overseas marketing scale, and enhanced its international influence. As a Chinese independent innovative enterprise, RainMed expands its global business on the basis of clinical practice, aiming to create world's leading innovative medical products, and has also made remarkable achievements. In addition to EU CE marking and China NMPA certification obtained in 2019, RainMed has three authoritative medical device registration certificates at present and successfully completed its registration in the Republic of Serbia and the Republic of South Africa, laying a solid market foundation for the continuous expansion of its commercial territory.

Bearing market demand in mind, RainMed Medical establishes the domestic market as well as exploring overseas market to achieve the global layout. In the year 2022, we have accelerated our application process for marketing access overseas, built a solid channel foundation with our self-developed products, and made continuous breakthroughs in the research and development of caFFR, caIMR and vascular interventional surgical robot FlashBot, which further fostered our customers' confidence in the company. With the increasing global attention and emphasis on precision medicine market, RainMed is expected to have a broader market prospect in the world this year.